Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Shares Issued (2018 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Shares Issued for 9 consecutive years, with $12.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 202.6% to $12.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.6 million, a 971.18% increase, with the full-year FY2025 number at $13.6 million, up 971.18% from a year prior.
  • Shares Issued was $12.0 million for Q4 2025 at Rhythm Pharmaceuticals, up from -$32.5 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $161.7 million in Q1 2021 to a low of -$32.5 million in Q3 2025.
  • A 5-year average of $19.3 million and a median of $1.1 million in 2024 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: soared 2545080.0% in 2022, then crashed 720.36% in 2025.
  • Rhythm Pharmaceuticals' Shares Issued stood at -$5000.0 in 2021, then skyrocketed by 2545080.0% to $127.2 million in 2022, then crashed by 99.88% to $159000.0 in 2023, then tumbled by 7468.55% to -$11.7 million in 2024, then skyrocketed by 202.6% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Shares Issued are $12.0 million (Q4 2025), -$32.5 million (Q3 2025), and $33.2 million (Q2 2025).